|
Real-time Estimate
Cboe BZX
23:59:32 02/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 82.28 USD | +11.11% |
|
+15.10% | -0.68% |
| 08-12 | Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating | MT |
| 08-07 | Mizuho Adjusts Tarsus Pharmaceuticals PT to $100 From $98, Maintains Outperform Rating | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TARSUS PHARMACEUTICALS, INC. | Biopharmaceuticals | +10.10% | +15.10% | -0.68% | +38.80% | +209.20% | 3.25B |  |  | |
- Stock Market
- Stocks
- TARS Stock
- Charts Tarsus Pharmaceuticals, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
